Oxford’s Vaccine Results Still Puzzle, AZ Expects Not To File With FDA

But UK, EU and India Decisions Anticipated

Partners hope non-US regulators will authorize early and then await later readouts to clarify vaccine's profile, but FDA is expected to hold out for US trial data.

Old Road Campus
Oxford University has led on the UK and Brazil trials, with AstraZeneca overseeing a US study which has yet to read-out.

Two weeks after first unveiling results, the full Oxford University and AstraZeneca’s Phase II/III COVID-19 vaccine studies have been published in The Lancet, but the paper has uncovered more shortcomings in the data to add to doubts raised two week ago when they were first presented.

Regulators in the UK, European Union and India are already reviewing the results, however, and may decide to grant emergency...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip